文献速递神经重症与神经感染

氟氢可的松治疗结核性脑膜炎患者脑性盐耗综合征的安全性和有效性:一项随机临床试验

Safety and Efficacy of Fludrocortisone in the Treatment of Cerebral Salt Wasting in Patients With Tuberculous Meningitis: A Randomized Clinical Trial.
PubMed 文献 · JAMA Neurol · 2018-01-01

这项在印度开展的单中心、开放标签、随机临床试验纳入36例结核性脑膜炎合并脑性盐耗综合征患者,比较仅输注盐水与盐水联合氟氢可的松的疗效。氟氢可的松组血钠正常化时间中位4天,显著早于对照组的15天(P=0.004),但住院死亡率及3个月、6个月残疾率无显著差异;氟氢可的松组深部边缘带梗死更少(1/18 vs 6/18,P=0.04),并报告严重低钾血症、高血压各2例及肺水肿1例。

要点

  • 氟氢可的松组血钠正常化时间中位4天,显著早于盐水组的15天(P=0.004)。
  • 两组住院死亡率、3个月及6个月残疾率无显著差异。
  • 氟氢可的松组深部边缘带梗死1/18(6%)vs 对照组6/18(33%),P=0.04。

核心结论

  • 氟氢可的松可使血清钠水平更早恢复正常,但未影响6个月时的结局。
  • 2例患者因严重不良反应停用氟氢可的松。
  • 该研究为氟氢可的松治疗结核性脑膜炎相关脑性盐耗综合征所致低钠血症的作用提供了II级证据。

研究设计与样本

  • 单中心、开放标签、随机临床试验,2015年10月至2017年4月在印度开展。
  • 患者按1:1随机分配至仅输注盐水组或盐水联合氟氢可的松组,两组均接受4种抗结核药物、泼尼松龙和阿司匹林的标准治疗。
  • 共纳入36例脑性盐耗综合征患者,每组18例;中位年龄30岁(范围20-46岁),男性19例(52.8%)。
  • 两组在人口学、临床和磁共振成像表现方面相匹配,随访至少6个月。

主要发现

  • 氟氢可的松组血钠恢复正常的中位时间为4天,显著早于仅输注盐水组的15天(P=0.004)。
  • 意向性治疗分析中,住院死亡率、3个月残疾率和6个月残疾率两组无显著差异。
  • 氟氢可的松组深部边缘带梗死发生1/18(6%),对照组为6/18(33%),P=0.04。
  • 氟氢可的松组发生严重低钾血症2例、高血压2例、肺水肿1例,2例因此停药。

关键数值与推荐

  • 主要终点为血清钠水平纠正所需时间;次要终点包括住院死亡率、3个月残疾、6个月残疾、卒中发生和严重不良反应。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Tuberculous meningitis is associated with high frequency of cerebral salt wasting. There is a paucity of objective information regarding the best method of treatment of this condition. OBJECTIVE: To evaluate the efficacy and safety of fludrocortisone in the treatment of cerebral salt wasting in patients with tuberculous meningitis. DESIGN, SETTING, AND PARTICIPANTS: This is a single-center, open-label, randomized clinical trial conducted from October 2015 to April 2017 in India. Patients were randomized in a 1:1 ratio to arms receiving saline only or saline plus fludrocortisone, in addition to a standard treatment of 4 antitubercular drugs, prednisolone, and aspirin. The 2 arms were matched for demographic, clinical, and magnetic resonance imaging findings. The patients were followed up for at least 6 months. INTERVENTIONS: Patients were randomized to a 0.9% solution of intravenous saline with 5 to 12 g per day of oral salt supplementation, with or without the addition of 0.1 to 0.4 mg of fludrocortisone per day. MAIN OUTCOMES AND MEASURES: The primary end point was the time needed to correct serum sodium levels; secondary end points were in-hospital deaths, disability at 3 months, disability at 6 months, occurence of stroke, and serious adverse reactions. RESULTS: Ninety-three patients with suspected tuberculous meningitis were recruited; 12 did not meet the inclusion criteria, including 4 with alternate diagnoses. A total of 37 patients with cerebral salt wasting were eligible for the study. One refused to participate, and therefore 36 patients were included, with 18 randomized to each group. The median (range) age was 30 (20-46) years, and 19 were male (52.8%). Those receiving fludrocortisone regained normal serum sodium levels after 4 days, significantly earlier than those receiving saline only (15 days; P = .004). In an intention-to-treat analysis, hospital mortality, disability at 3 months, and disability at 6 months did not differ significantly, but fewer infarcts occurred in the deep border zone in the group receiving fludrocortisone (1 of 18 [6%]) vs those in the control arm (6 of 18 [33%]; P = .04). Fludrocortisone was associated with severe hypokalemia and hypertension in 2 patients each, and pulmonary edema occurred in 1 patient. These adverse reactions necessitated discontinuation of fludrocortisone in 2 patients. CONCLUSIONS AND RELEVANCE: Fludrocortisone results in earlier normalization of serum sodium levels, but did not affect outcomes at 6 months. Fludrocortisone had to be withdrawn in 2 patients because of severe adverse effects. This study provides class II evidence on the role of fludrocortisone in treatment of hyponatremia associated with cerebral salt wasting in patients with tuberculous meningitis. TRIAL REGISTRATION: Clinical Trials Registry of India (ctri.nic.in) Identifier: CTRI/2017/10/010255.

来源:JAMA Neurol,查看原文。版权归原作者所有。

引用

  1. Misra UK, Kalita J, Kumar M, et al. Safety and Efficacy of Fludrocortisone in the Treatment of Cerebral Salt Wasting in Patients With Tuberculous Meningitis: A Randomized Clinical Trial. JAMA Neurol. 2018. PMID: 30105362. doi:10.1001/jamaneurol.2018.2178

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。